Inclusion criteria
|
1. Meet the diagnostic criteria for diabetes, and meet the diagnosis of type 2 diabetes;
2. Meet the LEAD diagnostic criteria;
3. The LEAD stage belongs to the Fontaine stage i;
4. Aged 35 to 70 years, gender is not limited;
5. Those who have started hypoglycemic, antihypertensive, and lipid-lowering western medicine treatment, and those who have been using the medicines stably for more than 3 months.
6. Willing to obey the doctor's treatment plan and cooperate with follow-up.
|
排除标准:
|
1.精神病患者,不能理解研究性质、范围或不能遵守医嘱者;
2.下肢皮肤有溃疡或坏疽、下肢中至重度水肿、或患有皮肤病者;
3.糖尿病酮症酸中毒、高血糖高渗综合征、糖尿病乳酸性酸中毒等急性并发症者;
4.恶性肿瘤患者及心、肝、肾严重功能不全者,有中风或心梗等心脑血管病史的者;
5.各种血液病及有出血倾向的患者,如血小板减少、白血病、呕血、吐血、便血、尿血、咯血、脑溢血,以及严重开放性损伤如胃肠急性穿孔等;
6.妊娠或哺乳期者;
7.过敏体质或曾有对本研究药物组成成分过敏者,因病情原因需长期服用抗血小板、抗凝、血管扩张药物者;
8.正在参加其它类似干预治疗者;
9.合并大动脉炎、雷诺病及血栓闭塞性脉管炎等其他外周性血管病,对本研究可造成明显影响的其他疾病者甲亢,醒固酮增多症,长期服用类固醇激素及其它影响血糖水平的药物者等;
10.可能影响研究的疗效性和安全性判断,依从性较差的患者。
|
Exclusion criteria:
|
1. Psychiatric patients who cannot understand the nature and scope of the research or who cannot comply with the doctor's orders;
2. Ulcers or gangrene on the skin of the lower extremities, moderate to severe edema of the lower extremities, or skin diseases;
3. Patients with acute complications such as diabetic ketoacidosis, hyperglycemia and hyperosmolar syndrome, and diabetic lactic acidosis;
4. Patients with malignant tumors, those with severe heart, liver, and kidney dysfunction, and those with a history of cardiovascular and cerebrovascular diseases such as stroke or myocardial infarction;
5. Patients with various blood diseases and bleeding tendency, such as thrombocytopenia, leukemia, hematemesis, hematemesis, blood in the stool, hematuria, hemoptysis, cerebral hemorrhage, and severe open injuries such as acute gastrointestinal perforation;
6. Those who are pregnant or breastfeeding;
7. Allergic constitution or those who have ever been allergic to the components of the drug in this study, who need to take antiplatelet, anticoagulant, and vasodilator drugs for a long time due to the disease;
8. Those who are participating in other similar interventions;
9. Combined with other peripheral vascular diseases such as Takayasu arteritis, Raynaud's disease and thromboangiitis obliterans, hyperthyroidism, hyperthyroidism, long-term use of steroid hormones and other diseases that may have a significant impact on this study. drugs, etc.;
10. Patients with poor compliance may affect the efficacy and safety of the study.
|